Pharmaceutical major Glenmark Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) has given its final nod to its US arm Glenmark Generics Inc. (GGI), USA, to market Hydrochloride tabs in variable strengths.

GGI would sell the tablets in the active strengths of 10mg, 25mg, 50mg and 100mg as the AB rated generic Pliva's equivalent Hydralazine Hydrochloride.

Hydralazine Hydrochloride tablets are prescribed for treating high blood pressure.

Moreover, Glenmark will start commence marketing and shipping their generic version in the US market.

GGI (formerly Glenmark Pharmaceuticals Inc., USA) set up its operations in 2003. It witnessed exponential growth in all regions and earned a notable status in the industry in a short span of just 5 years.

Presently, GGI's finished dose marketing range comprises around 30 products yielding 100 sku's.

At 2:17 p. m., the shares of Glenmark Pharmaceuticals gained 0.3% to trade at Rs 227.85 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 730 and a low of Rs 119.15 on BSE. Current EPS and P/E of the stock stood at 21.28 & 10.71 respectively.